Atorvastatin reduces plaque vulnerability in an atherosclerotic rabbit model by altering the 5-lipoxygenase pathway.
OBJECTIVE
The 5-lipoxygenase catalyzed formation of leukotriene lipid mediators is a mediator for inflammatory response in arteries. The present study investigated the relationship between atorvastatin and the 5-lipoxygenase pathway in an atherosclerotic rabbit model.


METHODS
Thirty male New Zealand White Rabbits were randomized into negative control, positive control and atorvastatin groups. At week 4, the rabbits were subjected to carotid balloon-dilation injury or carotid balloon-dilation injury, followed by treatment with atorvastatin. At week 12, all the animals were sacrificed. Plasma lipids, LTD(4), and 15-epi-lipoxin A(4) were measured using the enzymatic endpoint method and ELISA, respectively. RT-PCR was performed to detect the gene expression of 5-lipoxygenase-activating protein and cysLT1R in rabbit carotid arteries. Finally, histological analysis was used to evaluate the pathophysiological changes of rabbit carotid arteries.


RESULTS
The results showed atorvastatin markedly lowered serum lipids and LTD(4) levels compared with the control group. Similarly, mRNA expression of 5-lipoxygenase-activating protein and cysLT1R was significantly inhibited by atorvastatin. Decreased carotid plaque instability was evident in atorvastatin-treated animals, as demonstrated by a thickened elastic layer, less neointima hyperplasia and macrophage proliferation.


CONCLUSIONS
Atorvastatin may stabilize carotid plaque by regulating the 5-lipoxygenase pathway in atherosclerotic rabbits and delay the progression of atherosclerosis by exerting anti-inflammatory effects.
Department of Neurology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, PR China.
Guangyi
G
Zhou
Song
S
Ge
Dezhi
D
Liu
Gelin
G
Xu
Renliang
R
Zhang
Qin
Q
Yin
Wusheng
W
Zhu
Jieli
J
Chen
Xinfeng
X
Liu
D058927:5-Lipoxygenase-Activating Proteins; D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001094:Arachidonate 5-Lipoxygenase / Q000502:physiology*; D000069059:Atorvastatin; D016893:Carotid Stenosis / Q000097:blood / Q000235:genetics* / Q000473:pathology*; D002352:Carrier Proteins / Q000235:genetics*; D004195:Disease Models, Animal; D004547:Elastic Tissue / Q000187:drug effects / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D015870:Gene Expression / Q000187:drug effects / Q000235:genetics; D006538:Heptanoic Acids / Q000494:pharmacology*; D017998:Leukotriene D4 / Q000097:blood; D008055:Lipids / Q000097:blood; D044045:Lipoxins / Q000097:blood; D008565:Membrane Proteins / Q000235:genetics*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000473:pathology; D011758:Pyrroles / Q000494:pharmacology*; D012333:RNA, Messenger / Q000235:genetics*; D011817:Rabbits; D018077:Receptors, Leukotriene / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology
D058927:5-Lipoxygenase-Activating Proteins; D000924:Anticholesteremic Agents; D002352:Carrier Proteins; D006538:Heptanoic Acids; D008055:Lipids; D044045:Lipoxins; D008565:Membrane Proteins; D011758:Pyrroles; D012333:RNA, Messenger; D018077:Receptors, Leukotriene; C040527:lipoxin A4; D017998:Leukotriene D4; D000069059:Atorvastatin; D001094:Arachidonate 5-Lipoxygenase; C083169:leukotriene D4 receptor